CTCF binding has been mapped in a number of experimental approaches.
TNF-induced p65 (RELA or NFKB3, an NF-κB subunit) binding has been mapped genome-wide in a number of cells lines (THP-1, HeLa, A549, dendritic cells [ 15, 45, 46]).
The binding of C1q to human IgG1 is relatively well characterized, and most of the binding sites have been mapped to the C-terminal portion of the constant heavy chain (CH2) domains of the Fc fragment of the molecule.
For example, binding sites have been mapped for the stem cell regulator Scl in normal HSPCs [18] as well as the PML-RARA oncoprotein in promyelocytic leukaemia cells [19].
For comparison, Additional file 4 also shows the ChIP-seq peak in the fruA promoter region, where 2 MrpC binding sites have been mapped in vitro [ 30].
Although CSA-binding properties have been mapped to several VAR2CSA domains using in vitro binding assays [13], [33], [34], recent published data [35], [36] casts doubt on the specificity of single DBL domains for CSA.
Their albumin-binding sites have been mapped and these domains form the basis for a wide range of protein engineering approaches.
Several actin-binding sites have been mapped in the different α-actinin isoforms.
Two receptor-binding regions have been mapped on the Mo-RBD SU (Yoshimoto et al, 1993; MacKrell et al, 1996; Bae et al, 1997; Davey et al, 1997, 1999; Zavorotinskaya and Albritton, 1999).
Its domain IV, which consists of a tandem of immunoglobulin-like modules (IG2-IG15), is rich in such binding sites, which have been mapped to different modules obtained by recombinant production.
